← Back to Search

Vitamin

Nicotinamide Riboside for Gulf War Syndrome

N/A
Recruiting
Led By Michael Hoffmann, MD
Research Sponsored by Roskamp Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition
Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.)
Must not have
Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use birth control
Have contraindications, allergy, or sensitivity to NR, vitamin B3, or excipients (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

Summary

This trial tests whether taking Nicotinamide Riboside (NR), a form of vitamin B3, can help veterans with Gulf War Illness (GWI). GWI causes symptoms like fatigue and pain, possibly due to low energy levels in cells. NR aims to increase a molecule called NAD+ in the blood, which is crucial for cell energy production. The goal is to see if this can improve the health and well-being of these veterans. Nicotinamide Riboside (NR) is a newly discovered nicotinamide adenine dinucleotide (NAD+) precursor vitamin, recognized as safe for use in foods and dietary supplements.

Who is the study for?
This trial is for Gulf War veterans aged 47-70 with Gulf War Illness, who are medically stable and not on certain supplements. Women must use birth control if of childbearing potential. Those with allergies to the study drug or significant health issues can't participate.
What is being tested?
The trial tests if Nicotinamide Riboside (NR) increases plasma NAD+ levels in GWI patients using a double-blind method where neither participants nor researchers know who gets NR or placebo until after results are collected.
What are the potential side effects?
While specific side effects aren't listed here, NR is generally considered safe but could potentially cause mild upset stomach, fatigue, headaches, diarrhea, or indigestion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran diagnosed with Gulf War Illness according to CDC or Kansas criteria.
Select...
My weight is between 110 lbs and 440 lbs.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant, nursing, and if of childbearing age, I am using or willing to use birth control.
Select...
I am allergic to NR, vitamin B3, or certain pill ingredients.
Select...
I do not have any major health issues that could affect the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in plasma NAD+ levels
Secondary study objectives
Changes in immune biomarker profiles
Changes in lipid profiles
Other study objectives
Fatigue
Changes in general well-being
Memory
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Study Supplement: NRActive Control1 Intervention
26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.
Group II: ControlPlacebo Group1 Intervention
26 subjects will take the placebo during the first phase of the study (10 weeks).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Gulf War Syndrome (GWS) often focus on improving cellular energy production and reducing oxidative stress, similar to the mechanism of Nicotinamide Riboside (NR). NR increases NAD+ levels, a coenzyme essential for mitochondrial function and energy metabolism. This can enhance mitochondrial efficiency, reduce oxidative damage, and support cellular repair processes. These mechanisms are crucial for GWS patients, who frequently experience chronic fatigue, muscle pain, and cognitive impairments, potentially due to mitochondrial dysfunction and oxidative stress. By targeting these underlying issues, treatments like NR may help alleviate the symptoms and improve the quality of life for GWS patients.
The metabolism of glyceryl trinitrate to nitric oxide in the macrophage cell line J774 and its induction by Escherichia coli lipopolysaccharide.Potentiation of retinoic acid-induced U-937 differentiation into respiratory burst-competent cells by nitric oxide donors.Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.

Find a Location

Who is running the clinical trial?

Roskamp Institute Inc.Lead Sponsor
6 Previous Clinical Trials
474 Total Patients Enrolled
1 Trials studying Gulf War Syndrome
100 Patients Enrolled for Gulf War Syndrome
United States Department of DefenseFED
891 Previous Clinical Trials
332,426 Total Patients Enrolled
8 Trials studying Gulf War Syndrome
627 Patients Enrolled for Gulf War Syndrome
Nova Southeastern UniversityOTHER
95 Previous Clinical Trials
11,685 Total Patients Enrolled
2 Trials studying Gulf War Syndrome
330 Patients Enrolled for Gulf War Syndrome

Media Library

Nicotinamide Riboside (Vitamin) Clinical Trial Eligibility Overview. Trial Name: NCT05243290 — N/A
Gulf War Syndrome Research Study Groups: Study Supplement: NR, Control
Gulf War Syndrome Clinical Trial 2023: Nicotinamide Riboside Highlights & Side Effects. Trial Name: NCT05243290 — N/A
Nicotinamide Riboside (Vitamin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05243290 — N/A
~6 spots leftby Feb 2025